Cara Therapeutics Inc (NASDAQ:CARA) was upgraded by Vetr from a “hold” rating to a “strong-buy” rating in a note issued to investors on Friday, April 14th. The brokerage presently has a $19.90 target price on the biopharmaceutical company’s stock. Vetr‘s price objective suggests a potential upside of 18.10% from the stock’s previous close.
Other equities analysts have also issued research reports about the company. Piper Jaffray Companies reiterated an “overweight” rating and set a $23.00 price objective on shares of Cara Therapeutics in a research note on Friday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective (up previously from $20.00) on shares of Cara Therapeutics in a research note on Tuesday, January 31st. Zacks Investment Research lowered Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, March 14th. Canaccord Genuity restated a “buy” rating and set a $25.00 target price on shares of Cara Therapeutics in a research report on Friday, March 10th. Finally, Cantor Fitzgerald set a $24.00 price objective on Cara Therapeutics and gave the stock a “buy” rating in a report on Friday, March 10th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Cara Therapeutics currently has a consensus rating of “Buy” and an average target price of $26.17.
Cara Therapeutics (NASDAQ:CARA) traded down 0.65% on Friday, reaching $16.74. The company had a trading volume of 688,673 shares. The stock’s market capitalization is $544.17 million. The stock’s 50-day moving average price is $16.74 and its 200-day moving average price is $13.56. Cara Therapeutics has a 12-month low of $4.35 and a 12-month high of $20.90.
Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.73) by $0.08. The company had revenue of $0.91 million during the quarter, compared to the consensus estimate of $0.11 million. Cara Therapeutics’s revenue was up 12900.0% compared to the same quarter last year. During the same period last year, the business earned ($0.39) EPS. On average, equities research analysts anticipate that Cara Therapeutics will post ($2.35) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Cara Therapeutics Inc (CARA) Lifted to “Strong-Buy” at Vetr Inc.” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2017/05/19/cara-therapeutics-inc-cara-stock-rating-upgraded-by-vetr-inc-updated-updated-updated.html.
In related news, major shareholder Ventures Vi Lp Rho acquired 500,000 shares of the business’s stock in a transaction dated Friday, March 31st. The shares were acquired at an average price of $18.19 per share, with a total value of $9,095,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.70% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of CARA. FMR LLC bought a new stake in Cara Therapeutics during the fourth quarter worth $845,000. National Planning Corp raised its stake in Cara Therapeutics by 4.4% in the fourth quarter. National Planning Corp now owns 64,100 shares of the biopharmaceutical company’s stock worth $1,015,000 after buying an additional 2,700 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Cara Therapeutics by 37.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 229,626 shares of the biopharmaceutical company’s stock worth $2,133,000 after buying an additional 62,518 shares during the last quarter. Creative Planning increased its position in shares of Cara Therapeutics by 9.3% in the first quarter. Creative Planning now owns 14,340 shares of the biopharmaceutical company’s stock worth $264,000 after buying an additional 1,215 shares during the last quarter. Finally, State Street Corp increased its position in shares of Cara Therapeutics by 7.1% in the fourth quarter. State Street Corp now owns 348,531 shares of the biopharmaceutical company’s stock worth $3,244,000 after buying an additional 23,222 shares during the last quarter. 43.29% of the stock is currently owned by institutional investors and hedge funds.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
To view Vetr’s full report, visit Vetr’s official website.
What are top analysts saying about Cara Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cara Therapeutics Inc and related companies.